01.05.2019 • NewsAxensElaine Burridgepetchem

Axens Wins Petchems Contracts

Axens Wins Petchems Contracts (c) mmmx/Shutterstock
Axens Wins Petchems Contracts (c) mmmx/Shutterstock

French technology provider Axens has won contracts in China and India to supply several of its proprietary process units.

The most recent contract was awarded by China’s Shenghong Refining & Chemical (Lianyungang) Co., which has chosen Axens’ H-Oil and HyK hydrocracking processes for its petrochemical complex in Lianyungang, Jiangsu. The two single-train units will increase naphtha capacity by 3.6 million t/y.

Axens said the residue hydrocracking units will allow Shenghong to further improve its economic resilience and competitiveness. Jacques Rault, director of Axens’ middle distillates & conversion business line, said the routing optimization between the distillate hydrocracking HyK unit and the H-Oil unit delivers superior naphtha yields.

In early April, Axens announced it had been selected by HPCL Rajasthan Refinery (HRRL), a joint venture between Hindustan Petroleum Co. Ltd. (HPCL) and the government of Rajasthan in India, to supply several of its technologies for a 9 million t/y integrated refinery and petrochemical complex to be established in Pachpadra Tehsil of Barmer district, Rajasthan.

Axens will provide a naphtha hydrotreater, a C5-C6 isomerization unit, and an AlphaButol high-purity 1-butene unit, among several other facilities. “With these numerous technologies, HRRL will be well positioned to supply the market with cleaner fuels and also high-quality petrochemicals for the coming decades,” commented Axens chairman and CEO, Jean Sentenac.

A timescale and completion dates for both projects have not been disclosed.

 

######

www.axens.net

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.